We are live on ! Find out more
SLXN icon

Silexion Therapeutics

10 hedge funds and large institutions have $233K invested in Silexion Therapeutics in 2026 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,565% more capital inflows, than outflows

Capital inflows: $1.04M | Capital outflows: $38.9K

247.25% more ownership

Funds ownership: 5.18% → 252.44% (+247%)

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

67% more funds holding

Funds holding: 6 → 10 (+4)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
10
Holders Change
+4
Holders Change %
+66.67%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
1
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

SLXN Hedge Fund Activity: Q3 2026 in Review

10 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics (SLXN) for Q3 2026, worth a combined $233K — up 443% from $42.8K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new SLXN positions and 2 closed out — a net gain of 4 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $648K. The largest seller was HRT Financial, exiting entirely with an estimated $38K sold.

  • 10 institutional investors held Silexion Therapeutics (SLXN) as of Q3 2026, up from 6 in Q2 2026.
  • Funds reported $233K of Silexion Therapeutics stock for Q3 2026, up 443% quarter-over-quarter.
  • 6 funds opened new Silexion Therapeutics positions in Q3 2026 and 2 closed out, a net change of +4 holders.
  • The largest Silexion Therapeutics buyer in Q3 2026 was Armistice Capital, an estimated $648K added.
  • The largest Silexion Therapeutics seller in Q3 2026 was HRT Financial, an estimated $38K sold.

Based on aggregated 13F filings for Q3 2026.